Status:
COMPLETED
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Bundang CHA Hospital
Ulsan University Hospital
Conditions:
Pancreatic Cancer
Metastatic Pancreatic Cancer
Eligibility:
All Genders
19+ years
Brief Summary
In this study, clinical data of patients who received 2nd-line Nab-paclitaxel plus Gemcitabine (nab-P+GEM) after progression on 1st-line FOLFIRINOX will be reviewed retrospectively.
Detailed Description
FOLFIRINOX is one of standard 1 st-line regimens for patients with advanced PDAC. However, there is no globally established 2 nd-line regimen after the failure of FOLFIRINOX. Although gemcitabine-base...
Eligibility Criteria
Inclusion
- Pathologically confirmed pancreatic ductal adenocarcinoma
- Administration of 2nd-line nab-paclitaxel plus gemcitabine
- Progression on 1st-line FOLFIRINOX
Exclusion
- Pathologic diagnosis other than pancreatic ductal adenocarcinoma
- Administration of nab-paclitaxel plus gemcitabine as 3rd or greater lines of therapy
Key Trial Info
Start Date :
September 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2020
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT04133155
Start Date
September 16 2019
End Date
February 1 2020
Last Update
March 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 05505